These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 30299993)
1. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Raschi E; Mazzotti A; Poluzzi E; De Ponti F; Marchesini G Expert Opin Pharmacother; 2018 Dec; 19(17):1903-1914. PubMed ID: 30299993 [TBL] [Abstract][Full Text] [Related]
2. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G; Mikhailidis DP; Sahebkar A Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448 [TBL] [Abstract][Full Text] [Related]
3. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Cusi K Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272 [TBL] [Abstract][Full Text] [Related]
8. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Blazina I; Selph S Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920 [TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients. Adeghate EA Expert Opin Pharmacother; 2024 Feb; 25(3):223-232. PubMed ID: 38458647 [TBL] [Abstract][Full Text] [Related]
10. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366 [TBL] [Abstract][Full Text] [Related]
11. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Mazzotti A; Caletti MT; Marchignoli F; Forlani G; Marchesini G Dig Liver Dis; 2017 Mar; 49(3):235-240. PubMed ID: 28089623 [TBL] [Abstract][Full Text] [Related]
12. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Ng CH; Lin SY; Chin YH; Lee MH; Syn N; Goh XL; Koh JH; Quek J; Hao Tan DJ; Mok SF; Tan E; Dan YY; Chew N; Khoo CM; Siddiqui MS; Muthiah M Endocr Pract; 2022 Feb; 28(2):223-230. PubMed ID: 34606980 [TBL] [Abstract][Full Text] [Related]
14. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Yabiku K; Mutoh A; Miyagi K; Takasu N Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715 [TBL] [Abstract][Full Text] [Related]
15. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Lamos EM; Kristan M; Siamashvili M; Davis SN Expert Rev Clin Pharmacol; 2021 Jul; 14(7):837-852. PubMed ID: 33882758 [No Abstract] [Full Text] [Related]
16. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. An J; Sohn JH Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018 [TBL] [Abstract][Full Text] [Related]
18. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. Fan Y; He Z; Wang W; Li J; Hu A; Li L; Yan L; Li Z; Yin Q Biomed Pharmacother; 2018 Oct; 106():733-737. PubMed ID: 29990865 [TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Scheen AJ Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071 [TBL] [Abstract][Full Text] [Related]
20. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]